Novo Nordisk Inc Drug Patent Portfolio

Novo Nordisk Inc's Family Patents

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

Novo Nordisk confronts increasing competition from generic brands - MedWatch

19 Feb, 2026

Novo anticipates having an alternative to Ozempic available once the patent expires, according to Berlingske.

19 Feb, 2026

Disregard Ozempic: This Leading Obesity Medication Company Is Securing the Largest Share of the GLP-1 Market Boom.

19 Feb, 2026

Indian pharmaceutical company plans to offer Wegovy alternative at competitive prices, potentially up to a 60% discount.

18 Feb, 2026